Located along Maryland’s I-270 technology corridor, the almost 26,000sqft facility will accommodate the company’s future growth needs as the developer and manufacturer of lentiviral vectors (LVs) and proteins for a wide range of clinical and research applications, said Lentigen.
Two self-contained suites measuring 4,900sqft will allow the simultaneous production of both LVs and proteins in compliance with FDA-regulated current good manufacturing practices (cGMP), the company added.
Tim Ravenscroft, Lentigen’s CEO, said: “The new facility provides an opportunity to expand our research programs. More importantly, the addition of the cGMP manufacturing suites will allow us to manage our programs from the labs through manufacturing to the clinic.
“We plan to manufacture lentiviral products for clinical trials during 2009 and we will have capacity to handle manufacturing projects for collaborators as the market for lentiviral products expands.”